Arpida

Contact
arpida.ch
+41614179660

Arpida Ltd.

Duggingerstrasse 23
4153 Reinach AG
Switzerland
+41614179660
arpida.ch
Contact
Profile News
Contact

About Arpida

Arpida Ltd. (SWX: ARPN) is a Swiss biopharmaceutical company that focuses on the discovery and development of novel products for the treatment of microbial infections. Arpida has a fully-integrated platform to discover and develop drug candidates that seek to address the increasing levels of bacterial resistance to existing antibiotics and thus meet a growing medical need in both the hospital and community setting.

Read more about Arpida
Facts about Arpida
  • Focus : Manufacturer
  • Industry : Pharma

News about Arpida

Arpida

16-Dec-2009 | business & finance

Aravis leads Series B financing in Evolva SA Totalling CHF 44 M followed by a reverse merger of Evolva with Arpida

Aravis announced that it has co-led a highly complex transaction involving the second closing of a total Series B financing of CHF 44 M (USD 43 M) in ...

Read news
Arpida

23-Oct-2009 | business & finance

Evolva raises CHF 28 million in First Closing of Series B

Evolva SA announced a CHF 28 million first closing of its Series B financing round. The Series B financing is led by current investor Aravis and new ...

Read news
Arpida

12-Mar-2007 | research and development

Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

Arpida Ltd. announced positive results of in vitro microbiological studies with AR-2474 against a large panel of clinical isolates, including those ...

Read news
Arpida

26-Feb-2007 | science

Arpida re-aligns activities to support transition of its research portfolio

Arpida Ltd. announced the cessation of its research activities in Denmark. Arpida A/S, the Danish subsidiary of Arpida Ltd., has primarily focused on hit- ...

Read news
Arpida

24-May-2006 | research and development

Microbiological data confirm potent activity of AR-709 againt multi-drug resistant S. pneumoniae

Arpida Ltd. announced positive results from in vitro microbiological studies conducted with AR-709, a broad-spectrum, bactericidal antibiotic that Arpida ...

Read news
Arpida

23-Mar-2006 | research and development

Independent data review supports continuation of phase III programme with intravenous iclaprim

Arpida Ltd announced that it has received the recommendation from an independent Data and Safety Monitoring Board (DSMB) to continue the Phase III clinical ...

Read news
Show more news about Arpida

Here you will find Arpida Ltd.